Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Vella-Boucaud



Author of

  • +

    MA03 - Epidemiology, Risk Factors and Screening (ID 374)

    • Event: WCLC 2016
    • Type: Mini Oral Session
    • Track: Epidemiology/Tobacco Control and Cessation/Prevention
    • Presentations: 1
    • +

      MA03.06 - Cost Effectiveness of Chest Scan Screeing for Lung Cancer in Abestos Occupational Exposure Subjects: A Model Based Study (ID 5037)

      14:56 - 15:02  |  Author(s): J. Vella-Boucaud

      • Abstract
      • Presentation
      • Slides

      Background:
      The National Lung Screening trial (NLST) showed that screening with low-dose computed tomography (CT) compared with chest radiography reduced lung-cancer mortality. There is very few data's on subjects with occupational abestos exposure. We examined the cost-effectiveness of CT lung cancer screening in a french cohort of abestos post professional exposure subjets (APEXS cohort).

      Methods:
      We estimated mean lif-years, costs and incremental cost-effectiveness ration (ICER) for screening with low-dose CT compare to no screening in this population of abestose exposed subjects. Estimations of life-years gained were based on the efficacy of NLST trial aplpied to APEXS cohort, adjusted to sex and age. Costs were limited to directs costs, from the payer perspective. We also performed sensitiviy analysis based on several assumptions of screening program efficacy.

      Results:
      Compared with no screening, screening with low-dose CT, over a period of 2 years, will cost, for 1000 subjects of APEXS cohort 312 645 €, will provide 9.4 additional life-years. The corresponding ICER was 33 102 € per life-gained. Sensitiviyt analysis showed that this result is sensitive to screening program efficacy (number, stage, and survival diagnosed by the program).

      Conclusion:
      ICER of low-dose CT lung cancer program in a cohort of abestos post occupational exposure population appears as acceptable from the French health system.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.01 - Poster Session with Presenters Present (ID 453)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Epidemiology/Tobacco Control and Cessation/Prevention
    • Presentations: 1
    • +

      P1.01-036 - Lung Cancer Screening Program Is Cost Effective in French Setting: A Model Based Study (ID 5054)

      14:30 - 14:30  |  Author(s): J. Vella-Boucaud

      • Abstract

      Background:
      The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) as compared with chest radiography reduced lung cancer-mortality. There is no data's on the faisability and cost-effectiveness of CT lung cancer screening program in the French setting.

      Methods:
      We estimated mena life-years gaineds, costs and incremental cost-effectiveness ratio (ICER) for screening with low-dose CT compare to no screening. Estimations of life-years gained were based on the efficacy of NLST trail applied to the general french population using the same inclusion criteria's that NLST trail (age of 55 to 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since quitting) adjusted to sex, age and smoking status. Costs were limited to directs costs from the payers perspective. We also performed sensitivity analysis based on several asssumptions of program efficacy.

      Results:
      The target population was 5 551 141 subjects. Compared with no screening, screening with low-dose CT, over a period of 2 years, will have an additional cost of 941 978 €, will provide 52.4 additional year of life with a corresponding ICER of 17 969 € per year gained. Sensititiviy analysis showed that this result is sensitive to program efficacy (number, stage and survival of lung cancer diagnosed by the program) and to subjects compliance rate to the program.

      Conclusion:
      Cost effectiveness of CT lung cancer screening program in a French population using the same main inclusion criteria and outcomes of NLST trial appears as acceptable from the french health system